BioArctic AB
STO:BIOA B

Watchlist Manager
BioArctic AB Logo
BioArctic AB
STO:BIOA B
Watchlist
Price: 202 SEK -5.08%
Market Cap: 17.8B SEK
Have any thoughts about
BioArctic AB?
Write Note

BioArctic AB
Investor Relations

In the heart of Sweden, BioArctic AB carves its niche as a pioneering biopharmaceutical company with a resolute focus on neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases. Founded in 2003 by the innovative minds of Professor Lars Lannfelt and Dr. Pär Gellerfors, the company draws on cutting-edge science to develop novel treatments that target the underlying causes of these debilitating conditions. BioArctic’s scientific journey is rooted in its strategic use of monoclonal antibodies to halt or reverse the progression of neurological diseases. By zeroing in on the amyloid beta proteins and alpha-synuclein aggregates that play significant roles in Alzheimer’s and Parkinson’s diseases, respectively, BioArctic aims to provide therapies that go beyond mere symptom management to address the fundamental disease processes.

At the core of BioArctic’s financial engine lies its collaborative business model, where strategic partnerships with pharmaceutical giants like Eisai and AbbVie are pivotal. These alliances not only bolster BioArctic’s research capabilities but also generate substantial revenue through milestone payments and royalties. Such collaborations allow BioArctic to leverage the vast distribution networks and financial muscle of its partners, facilitating the global commercialization of its therapies once they achieve regulatory approval. As the company continues to advance its pipeline through rigorous clinical trials, its combination of scientific rigor and strategic partnerships positions it as a formidable player in the quest to unravel and treat complex neurodegenerative diseases. Through its relentless innovation and well-crafted alliances, BioArctic stands at the forefront of transforming medical treatment for millions worldwide.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Dr. Gunilla Osswald Ph.D.
President & CEO
No Bio Available
Dr. Pär Gellerfors
Co-Founder, Senior VP of Business Strategy & Director
No Bio Available
Prof. Lars Lannfelt
Co-Founder, Senior VP of Medical science & Director
No Bio Available
Mr. Anders Martin-Lof M.B.A., M.Sc.
Chief Financial Officer
No Bio Available
Ms. Johanna Fälting
Chief Research Officer & Head of Research
No Bio Available
Mr. Christer Möller
VP of Pre-Clinical Development & Chief Scientific Officer
No Bio Available
Mr. Oskar Bosson
VP and Head of IR & Communication
No Bio Available
Mr. Leif Gallo LL.M.
General Counsel and Head of Legal & IP
No Bio Available
Mr. Harald Borgeke
Head of Public Affairs
No Bio Available
Ms. Frida Lekander
Head of Marketing
No Bio Available

Contacts

Address
STOCKHOLM
Stockholm
Warfvinges vag 35
Contacts
+4686956930.0
www.bioarctic.se